Persistent response to pneumococcal vaccine in individuals supplemented with a novel water soluble extract of Uncaria tomentosa, C-Med-100.
A human intervention study was carried out using male volunteers attending a General Practice Clinic in New York City involving comparison of individuals supplemented with 350 mg x 2 C-Med-100 daily dose for two months with untreated controls for their abilities to respond to a 23 valent pneumococcal vaccine. C-Med-100 is a novel nutraceutical extract from the South American plant Uncaria tomentosa or Cat's Claw which is known to possess immune enhancing and antiinflammatory properties in animals. There were no toxic side effects observed as judged by medical examination, clinical chemistry and blood cell analysis. However, statistically significant immune enhancement for the individuals on C-Med-100 supplement was observed by (i) an elevation in the lymphocyte/neutrophil ratios of peripheral blood and (ii) a reduced decay in the 12 serotype antibody titer responses to pneumococcal vaccination at 5 months.
Lamm
S
S
Department of Cell and Molecular Biology, Section of Tumor and Immune Biology, University of Lund, Sweden.
Sheng
Y
Y
Pero
R W
RW
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D001772:Blood Cell Count; D003430:Cross-Sectional Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D018514:Plant Structures; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D012016:Reference Values; D013296:Streptococcus pneumoniae / Q000276:immunology; D016896:Treatment Outcome; D032070:Uncaria
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; C406667:C-MED-100; D010936:Plant Extracts; D022242:Pneumococcal Vaccines